Gene-editing therapy PBGENE-HBV shows encouraging trial results
PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…
